Predictive Factors for Complete Pathologic Response in Luminal Breast Cancer: Impact of Ki67 and HER2 Low Expression

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2024 Dec 30

PMID 39734711

Authors

Isabel Miras

Ana Gil

Marta Benavent

Maria Angeles Castilla

Begona Vieites

Maria Angeles Dominguez-Cejudo

Sonia Molina-Pinelo

Lina Alfaro

Javier Frutos

Manuel Ruiz-Borrego

Alejandro Falcon

Monica Cejuela

Javier Salvador-Bofill

Affiliations

Soon will be listed here.

Abstract

Background: Complete pathological response to neoadjuvant treatment (NAT) in breast cancer is associated with prolonged survival. Compared to other breast cancer immunophenotypes, luminal tumors are the least chemosensitive with low rates of pathological response within this molecular subtype. Thus, finding predictors of response in this subset remains challenging. The emerging concept of low human epidermal growth factor receptor 2 (HER2) expression has led to a repurpose of the current prognostic system. Little is known about its correlation with response to NAT.

Objectives: This study aims to evaluate predictors of response in early-stage luminal breast cancer receiving neoadjuvant chemotherapy.

Design: A total of 252 luminal patients who received NAT were retrospectively assessed in this cohort study.

Methods: We analyzed the correlation of ki67 and HER2 low expression with the rate of pathologic response. Using ki67 as a continuous variable and applying the receiver operating characteristic curves method.

Results: We identified that in patients with a ki67 expression level >37%, the probability of having a complete pathological response was 4.80 times higher (odds ratio = 4.80, 95% confidence interval: 1.92-12.04). In Her2-low breast cancer patients, Her2 expression did not correlate with a better response rate.

Conclusion: In our study, a ki67 expression value greater than 37% constitutes a predictive biomarker of pathological complete response in the subgroup of patients with luminal B tumors and could be considered, therefore, an indicator for treatment decisions in this subgroup.

References

Hayashi N, Yagata H, Tsugawa K, Kajiura Y, Yoshida A, Takei J . Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER HER2 Breast Cancer: A Prospective Phase II Study. Clin Breast Cancer. 2020; 20(6):462-468. DOI: 10.1016/j.clbc.2020.09.007. View

de Moura Leite L, Cesca M, Tavares M, Santana D, Saldanha E, Guimaraes P . HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat. 2021; 190(1):155-163. DOI: 10.1007/s10549-021-06365-7. View

Chen X, He C, Han D, Zhou M, Wang Q, Tian J . The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017; 13(9):843-857. DOI: 10.2217/fon-2016-0420. View

Freeman J, Shubeck S, Howard F, Chen N, Nanda R, Huo D . Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. NPJ Breast Cancer. 2023; 9(1):33. PMC: 10164191. DOI: 10.1038/s41523-023-00536-z. View

Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D . Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2021; 23(1):149-160. PMC: 9455620. DOI: 10.1016/S1470-2045(21)00589-1. View

Denkert C, Loibl S, Muller B, Eidtmann H, Schmitt W, Eiermann W . Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013; 24(11):2786-93. DOI: 10.1093/annonc/mdt350. View

Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R . Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol. 2014; 32(34):3883-91. DOI: 10.1200/JCO.2014.55.2836. View

Polley M, Leung S, McShane L, Gao D, Hugh J, Mastropasqua M . An international Ki67 reproducibility study. J Natl Cancer Inst. 2013; 105(24):1897-906. PMC: 3888090. DOI: 10.1093/jnci/djt306. View

Ayala de la Pena F, Antolin Novoa S, Gavila Gregori J, Gonzalez Cortijo L, Henao Carrasco F, Martinez Martinez M . SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clin Transl Oncol. 2023; 25(9):2647-2664. PMC: 10425528. DOI: 10.1007/s12094-023-03215-4. View

10.

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

11.

Faneyte I, Schrama J, Peterse J, Remijnse P, Rodenhuis S, van de Vijver M . Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003; 88(3):406-12. PMC: 2747533. DOI: 10.1038/sj.bjc.6600749. View

12.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72. DOI: 10.1016/S0140-6736(13)62422-8. View

13.

Mauri D, Pavlidis N, Ioannidis J . Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3):188-94. DOI: 10.1093/jnci/dji021. View

14.

Ma Q, Liu Y, She T, Liu X . The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients. Breast Cancer (Dove Med Press). 2024; 16:117-126. PMC: 10929654. DOI: 10.2147/BCTT.S451617. View

15.

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020; 144(5):545-563. DOI: 10.5858/arpa.2019-0904-SA. View

16.

Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J . High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist. 2016; 21(2):150-5. PMC: 4746087. DOI: 10.1634/theoncologist.2015-0312. View

17.

Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M . International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011; 2011(43):147-51. DOI: 10.1093/jncimonographs/lgr037. View

18.

Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J, Just M . Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8):1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. View

19.

Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A . HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. BMC Cancer. 2022; 22(1):1081. PMC: 9585737. DOI: 10.1186/s12885-022-10163-9. View

20.

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View